Search results for: 'biologics contract development'

Biological age tracking is emerging as a complementary approach to understanding human health, offering a more nuanced assessment of physiological state than chronological age alone. This report examines the evolving landscape of biological aging platforms, with a focus on molecular and omics-based technologies including epigenetic, proteomic, tran...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent developments for intelligent drug discovery solutions, precision oncology and novel biologics. The TOE also comprises innovations across stem cell therapies and radiotherapies.The Life Science, Health & Wellness TOE will feature d...

25 Jul 2016  |  Europe  |  Market Research

Analysis of the Global Biologics API Market

Redefining the Future of Biologics through Target-specific Drugs and Novel Technologies

Infographics

×

This study provides an insight into the global biologics active pharmaceutical ingredients (API) market. According to the US FDA, “Biological products, or biologics, are medical products made from a variety of natural sources (human, animal, or microorganism). Biologics are intended to treat diseases & medical conditions and prevent or diagnose dis...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

Immuno-oncology (I-O) therapies target tumors by harnessing the host s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, includ...

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain. The growing incidence of chronic diseases propels t...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in oncology, immunology, autoimmune disorders, and precision medicine, highlighting next-generation biologics, bispecific antibodies, kinase inhibitors, molecular glues, and antibody engineering platforms. The...

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent technology advances across cell & gene therapies, immunotherapies, intelligent drug discovery approaches, automated biomanufacturing and microbiome sciences. The TOE also encompasses recent developments in proteomics, drug deliver...